Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin

Keyphrases

• Adverse Effects 100%
• Adjuvant Therapy 100%
• Growth Factors 100%
• Peg-interferon and Ribavirin 100%
• Hepatitis C Virus Therapy 50%
• Hepatitis C Virus 50%
• United States 50%
• Therapy Discontinuation 50%
• Patient Demographics 50%
• Combination Therapy 50%
• Hematopoietic Growth Factors 50%
• Response Rate 50%
• Effective Treatment 50%
• Chronic Infection 50%
• Sustained Virological Response 50%
• Dose Reduction 50%
• Chronic Hepatitis C Virus Infection 50%
• Combination Antiviral Therapy 50%
• Dose Interruption 50%
• Hematological Adverse Events 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 100%
• Growth Factor 100%
• Ribavirin 100%
• Peginterferon 100%
• Hepatitis C Virus 66%
• Combination Therapy 33%
• Infection 33%
• Chronic Hepatitis C 33%
• Antiviral Therapy 33%
• Hemopoietic Growth Factor 33%
• Virotherapy 33%